Heads up: we show every live trademark, plus inactive ones from the last 5 years, in the United States, Singapore, Canada, Australia and France. India is looked up live when you search, so it is not a saved copy of every mark, and it can be busy some days. Data is only as fresh as each country publishes it, and some countries aren’t included yet, so a brand can be registered even if it doesn’t show here. Always check the official record before you use a name. This is not legal advice.
KERNAL
Third Extension - Granted
Show more
Class 1: Chemicals for use in biotechnological manufacturing processes; Chemicals for use in biotechnological product development; Biochemicals for use in biotechnological manufacturing processes and product development, namely, protein-encoding nucleic acids and polypeptide-encoding nucleic acids related to treating cancers, auto-immune diseases, cardio metabolic diseases, infectious diseases, inflammatory diseases, and metabolic diseases; nucleotides for scientific and research use; biochemical reagents commonly known as probes, for detecting and analyzing molecules in protein or nucleotide arrays; protein arrays and nucleotide arrays for scientific and medical research; nucleic acid for laboratory…
Class 5: Medical, biological, and pharmaceutical preparations for treating cancers, auto-immune diseases, cardio metabolic diseases, infectious diseases, inflammatory diseases, and metabolic diseases; RNA-based therapeutics and therapeutic agents for in vivo, ex vivo, or in situ treatment of cancers, auto-immune diseases, cardio metabolic diseases, infectious diseases, inflammatory diseases, and metabolic diseases; medical, biological and pharmaceutical preparations containing lipid nanoparticles for the prevention and treatment of cancers, auto-immune diseases, cardio metabolic diseases, infectious diseases, inflammatory diseases, and metabolic diseases; RNA-based therapeutics and therapeutic agents…
Class 1 – ChemicalsClass 5 – Pharmaceuticals & supplements
Status timeline
- 21 Jul 2022Application filedNew Application Entered
- 3 May 2023Assigned to an examining attorneyAssigned To Examiner
- 3 May 2023Office action issuedNon-Final Action Written
- 30 Oct 2023Response to office action filedTeas Response To Office Action Received
- 4 Dec 2023Final refusal issuedFinal Refusal Mailed
- 1 Aug 2024Approved for publicationApproved For Pub - Principal Register
- 3 Sep 2024Published for oppositionPublished For Opposition
- 29 Oct 2024Notice of allowance issued — statement of use requiredNoa Mailed - Sou Required From Applicant
- 21 Apr 2025Statement-of-use extension 1 grantedSou Extension 1 Granted
- 28 Oct 2025Statement-of-use extension 2 grantedSou Extension 2 Granted
- 28 Apr 2026Statement-of-use extension 3 grantedSou Extension 3 Granted
All 40 events
| 2026-04-28 | Sou Extension 3 Granted |
| 2026-04-28 | Notice Of Approval Of Extension Request E-Mailed |
| 2026-04-27 | Sou Teas Extension Received |
| 2026-04-27 | Sou Extension 3 Filed |
| 2025-10-29 | Notice Of Approval Of Extension Request E-Mailed |
| 2025-10-28 | Sou Teas Extension Received |
| 2025-10-28 | Sou Extension 2 Filed |
| 2025-10-28 | Sou Extension 2 Granted |
| 2025-04-22 | Notice Of Approval Of Extension Request E-Mailed |
| 2025-04-21 | Sou Teas Extension Received |
| 2025-04-21 | Sou Extension 1 Filed |
| 2025-04-21 | Sou Extension 1 Granted |
| 2024-10-29 | Noa Mailed - Sou Required From Applicant |
| 2024-09-03 | Published For Opposition |
| 2024-09-03 | Official Gazette Publication Confirmation E-Mailed |
| 2024-08-14 | Notification Of Notice Of Publication E-Mailed |
| 2024-08-01 | Examiners Amendment -Written |
| 2024-08-01 | Examiners Amendment E-Mailed |
| 2024-08-01 | Notification Of Examiners Amendment E-Mailed |
| 2024-08-01 | Examiner's Amendment Entered |
| 2024-08-01 | Approved For Pub - Principal Register |
| 2023-12-04 | Final Refusal Mailed |
| 2023-12-04 | Final Refusal E-Mailed |
| 2023-12-04 | Notification Of Final Refusal Emailed |
| 2023-10-30 | Teas Response To Office Action Received |
| 2023-10-30 | Correspondence Received In Law Office |
| 2023-10-30 | Teas/Email Correspondence Entered |
| 2023-10-18 | Teas Change Of Owner Address Received |
| 2023-10-18 | Applicant/Correspondence Changes (Non-Responsive) Entered |
| 2023-10-18 | Teas Revoke/App/Change Addr Of Atty/Dom Rep Received |
| 2023-10-18 | Attorney/Dom.rep.revoked And/Or Appointed |
| 2023-10-18 | Teas Change Of Correspondence Received |
| 2023-07-21 | Application Extension To Response Period - Received |
| 2023-07-21 | Application Extension Granted/Receipt Provided |
| 2023-05-03 | Assigned To Examiner |
| 2023-05-03 | Non-Final Action Written |
| 2023-05-03 | Non-Final Action E-Mailed |
| 2023-05-03 | Notification Of Non-Final Action E-Mailed |
| 2022-08-08 | New Application Office Supplied Data Entered |
| 2022-07-21 | New Application Entered |
Goods & services by class
Class 1 Chemicals
Chemicals for use in biotechnological manufacturing processes; Chemicals for use in biotechnological product development; Biochemicals for use in biotechnological manufacturing processes and product development, namely, protein-encoding nucleic acids and polypeptide-encoding nucleic acids related to treating cancers, auto-immune diseases, cardio metabolic diseases, infectious diseases, inflammatory diseases, and metabolic diseases; nucleotides for scientific and research use; biochemical reagents commonly known as probes, for detecting and analyzing molecules in protein or nucleotide arrays; protein arrays and nucleotide arrays for scientific and medical research; nucleic acid for laboratory…
Class 5 Pharmaceuticals & supplements
Medical, biological, and pharmaceutical preparations for treating cancers, auto-immune diseases, cardio metabolic diseases, infectious diseases, inflammatory diseases, and metabolic diseases; RNA-based therapeutics and therapeutic agents for in vivo, ex vivo, or in situ treatment of cancers, auto-immune diseases, cardio metabolic diseases, infectious diseases, inflammatory diseases, and metabolic diseases; medical, biological and pharmaceutical preparations containing lipid nanoparticles for the prevention and treatment of cancers, auto-immune diseases, cardio metabolic diseases, infectious diseases, inflammatory diseases, and metabolic diseases; RNA-based therapeutics and therapeutic agents…
Owner details
See the official record for contact details. View official record →
Source & freshness
Source: the official United States trademark register. This record was last updated on 29 Apr 2026; the index was built on 20 Nov 2026 and covers data through 31 Aug 2026. View official record → If the two differ, the official record is correct.